医学
癌症
免疫疗法
免疫学
不利影响
免疫系统
免疫检查点
佐剂
肿瘤科
内科学
摘要
People with cancer are known to have a high risk of thromboembolism, (and, paradoxically, bleeding) and much work has been directed to understanding its epidemiology, outcomes, and underlying pathophysiology.[1] Treatment of cancer itself—both locoregional and systemic—has been the focus of much of this work.[2] Systemic therapy against cancer is currently in the midst of a paradigm shift. To say that immunotherapy—in particular, immune checkpoint inhibitor (ICI) therapy—has transformed the systemic therapy of cancer is an understatement. The advent of this class of drugs—which works by enhancing antitumor immunity secondary to blocking down-regulators of the immune response such as programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4)—has substantially increased survival and cure rates in people with various stages and types of cancers. All told, regulatory authorities have approved 90 indications for at least 11 agents worldwide, ranging from neoadjuvant and adjuvant therapy in curative settings to palliative (but life-extending) treatment in metastatic settings.[3] [4] Yet, these agents are not without toxicity. By creating a pro-inflammatory milieu, ICI therapy is known to be associated with inflammatory or autoimmune side effects that affect multiple organ systems and are together known as immune-related adverse events (IRAEs).[5] [6] Although initial toxicity reports did not include vascular effects, emerging data from various groups focused on hematologic toxicities have pointed to a high rate of an old complication associated with these new agents: venous thromboembolism (VTE).[7]
科研通智能强力驱动
Strongly Powered by AbleSci AI